Validation of a data-driven clustering model for MASLD: Evidence from three large-scale Asian cohorts

作者：Xiaodong Zhou, Sherlot Juan Song, Chloe Yitian Guo, Qin‐Fen Chen, Grace Lai‐Hung Wong, Tong Ye, George Boon‐Bee Goh, Yong Mong Bee, Liyou Lian, Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Siyi Lei, Wen‐Yue Liu, Rui Fan, Cheng-Lv Hong, Giovanni Targher, Christopher D. Byrne, Guillemette Marot, Violeta Raverdy, François Pattou, Daniel Yan Zheng Lim, Vincent Wai‐Sun Wong, Ming‐Hua Zheng · 发表于：JHEP Reports · 年份：2025 · DOI：10.1016/j.jhepr.2025.101645 · 被引用次数：6 · 研究领域：Liver Disease Diagnosis and Treatment、Diabetes, Cardiovascular Risks, and Lipoproteins、Liver Disease and Transplantation

Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition that presents varying risks for liver-related and cardiovascular complications. Clustering methods have identified distinct MASLD subtypes, yet their applicability to Asian populations remains unclear. This study aims to validate a MASLD clustering model using clinical variables from three Asian cohorts: Wenzhou Real-World (WRW), Hong Kong Clinical Data Analysis and Reporting System (CDARS), and SingHealth Diabetes Registry. Methods: , alanine aminotransferase, LDL-cholesterol, and triglycerides. Outcomes included major adverse cardiovascular events (MACE), liver-related events (LRE), and new-onset type 2 diabetes (T2DM). They were analyzed using Cox regression risk models and Kaplan-Meier analyses to assess risk and incident events across MASLD clusters. Results: <0.001). Conclusions: The proposed MASLD clustering model is applicable to Asian populations, facilitating personalized treatment and optimizing outcomes. Impact and implications: This study provides scientific justification for applying a validated clustering model to metabolic dysfunction-associated steatotic liver disease (MASLD), demonstrating that patient subgroups identified by data-driven methods carry distinct risks for cardiovascular and liver-related outcomes. These findings are important for clinicians, researchers, and policymakers as they highlight that MASLD is not a uniform disease but rath...